NASDAQ:NRIX Nurix Therapeutics Q3 2025 Earnings Report $9.04 -0.16 (-1.74%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$8.98 -0.05 (-0.61%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Nurix Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.84Beat/MissN/AOne Year Ago EPSN/ANurix Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$16.06 millionBeat/MissN/AYoY Revenue GrowthN/ANurix Therapeutics Announcement DetailsQuarterQ3 2025Date10/10/2025TimeBefore Market OpensConference Call DateFriday, October 10, 2025Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Nurix Therapeutics Earnings HeadlinesNurix Therapeutics, Inc. (NRIX) Presents At Baird Global Healthcare Conference 2025 (Transcript)September 12 at 10:03 AM | seekingalpha.comNurix Therapeutics, Inc. (NRIX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)September 12 at 9:56 AM | seekingalpha.comAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best." | Brownstone Research (Ad)Nurix Therapeutics, Inc. (NRIX) Presents At H.C. Wainwright 27th Annual Global Investment Conference TranscriptSeptember 11 at 4:01 AM | seekingalpha.comNurix Therapeutics, Inc. (NRIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10 at 10:10 AM | seekingalpha.comNurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 - SlideshowSeptember 5, 2025 | seekingalpha.comSee More Nurix Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nurix Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nurix Therapeutics and other key companies, straight to your email. Email Address About Nurix TherapeuticsNurix Therapeutics (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology. The company’s pipeline includes multiple programs in various stages of development. Among these are targeted protein degraders designed to eliminate key signaling proteins implicated in B-cell malignancies and inflammatory disorders. Nurix advances both proprietary and partnered assets, leveraging its Maestro™ platform to generate novel therapeutic candidates that reflect its expertise in medicinal chemistry, structural biology and protein degradation technologies. Founded in 2015 and headquartered in San Francisco, California, Nurix collaborates with leading pharmaceutical companies to accelerate discovery and development. These strategic alliances complement the company’s in-house capabilities, enabling the translation of early research into clinical candidates and enhancing its capacity to address diseases that have proved difficult to treat with conventional approaches. Under the leadership of Chief Executive Officer Christalynn Sayers and an experienced management team, Nurix Therapeutics continues to advance its proprietary pipeline through clinical trials and regulatory engagements. The company remains committed to pioneering new modalities that selectively dismantle disease drivers, with the goal of delivering transformative medicines to patients worldwide.View Nurix Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Celsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
